US2020316158A1PendingUtilityA1
Collagen 7 compositions and methods of using the same
Est. expiryDec 23, 2035(~9.4 yrs left)· nominal 20-yr term from priority
A61K 38/39A61P 17/02A61K 47/26A61K 47/183C07K 14/78A61Q 19/08A61K 38/014A61K 8/65A61K 8/60A61K 8/4993A61K 8/44A61K 8/24A61K 8/20A61K 47/10A61K 9/0019
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure relates to compositions comprising collagen 7 and methods of using the same to treat DEB.
Claims
exact text as granted — not AI-modified1 . A composition comprising at least 0.5 mg/ml recombinant collagen 7 (rCo17) in a formulation comprising arginine.
2 . The composition of claim 1 , wherein rCol7 is at a concentration of about 1.0 mg/ml to about 4.0 mg/ml.
3 . The composition of claim 2 , wherein rCol7 is at a concentration of about 1.0 mg/ml to about 2.0 mg/ml.
4 . The composition of claim 3 , wherein the formulation further comprises 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose and 0.05% (v/v) polysorbate 20.
5 . The composition of claim 4 for use of medicine administered to a subject in need through infusion wherein the infusion lasts at least 60 minutes.
6 . A method for treating dystrophic epidermolysis bullosa comprising administering to a subject in need thereof an effective amount of a composition that comprises about 1.0 mg/ml to about 4.0 mg/ml recombinant collagen 7.
7 . The method of claim 6 wherein the composition is administrated to the subject in need by intravenous administration.
8 . A method for increasing closure between epidermis and dermis of the wounded skin in a subject comprising administering to the subject a composition comprising a recombinant collagen 7 in an arginine containing formulation.
9 . The method of claim 8 wherein the composition is administrated to the subject in need by intravenous administration.
10 . The method of claim 6 wherein the composition comprises about 1.0 mg/ml to about 2.0 mg/ml recombinant collagen 7.
11 . The method of claim 10 wherein the composition further comprises 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose and 0.05% (v/v) polysorbate 20.Join the waitlist — get patent alerts
Track US2020316158A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.